Ethical Compliance Statement: According to the French ethic and regulatory law (public health code) retrospective studies based on the exploitation of usual care data do not require to be submitted at an ethics committee but they have to be declared or covered by reference methodology of the French National Commission for Informatics and Liberties (CNIL). The authors confirm that the approval of an institutional review board was not required for this work. All patients received written information about the study, and could express their opposition rights through the cohort website in accordance to EU General Protection Data Regulation rules (https://parkinsonnetwork/la-cohorte-ns-park) (https://parkinson.network/). A collection and computer processing of personal and medical date was implemented to analyze the results of the research. Toulouse University Hospital signed a commitment of compliance to the reference methodology MR‐004 of the French National Commission for Informatics and Liberties (CNIL). After evaluation and validation by the data protection officer and according to the General Data Protection Regulation*, this study completing all the criteria, it is register in the register of data study of the Toulouse University Hospital (number's register: RnIPH 2023‐39) and cover by the MR‐004 (CNIL number: 2206723 v 0). We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

Funding Sources and Conflicts of Interest: No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work.

Financial Disclosures for the previous 12 months: CD received Honoraria to speak from Téva Santé and Expression Santé, consultancies for Téva Santé. GTS received consulting and advisory board honoraria from Alzheimer's Association, Critical Path Institute, International Parkinson and Movement Disorder Society, Huntington Study Group, Lilly USA, Michael J. Fox Foundation for Parkinson's Research, Neurocrine Biosciences, Inc., Octave Bioscience, Pfizer, Inc., Vima Therapeutics, Inc., WCG Clinical, Inc. He has received grants from Critical Path Institute, CHDI Management, Inc., International Parkinson and Movement Disorder Society, Michael J. Fox Foundation for Parkinson's Research, Ottawa Hospital Research Institute, University of California at San Diego, University of California at San Francisco. TAM received consulting and advisory board membership honoraria with Abbvie, International Parkinson and Movement Disorder Society, AbbVie, CHDI Foundation/Management, Merz, WAVE pharmaceutical, PTC therapeutics and Roche. He has research grants with EU Joint Program—Neurodegenerative Disease Research, uOBMRI, Roche, Ontario Research Fund, CIHR, Michael J. Fox Foundation for Parkinson's Research, Parkinson Canada, Parkinson Research Consortium and Brain Canada. He receives salary with University of Ottawa Medical Associates. RB received a travel grant from Lusofarmaco. Alvaro Sanchez‐Ferro received grants or contracts from MDS (eDiary project), and Instituto de Salud Carlos III (reference number P122/01177); consulting fees from AbbVie, Boston Scientific, Esteve, Orion Pharma, Prim; and Roche and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie, Bayer, Esteve, MDS Society, EAN, Novartis, Monitor, Organon, Roche, SEN, Stada, Teva, and Zambon. Salary: Leuko Labs and Hospital 12 de Octubre. Royalties from Patents. Stock: Leuko Labs. MHST received salary—Rush University; Professional Societies: working group supported by the International Parkinson and Movement Disorder Society. CG‐S received consulting with honoraria: Instituto de Salud Carlos III. Grants: Community of Madrid Grant for Research Assistant. Funding to attend a scientific meeting: Esteve. CT has received honoraria or travel grants from AbbVie and Adelia. JCC has served in advisory boards for Alzprotect, Bayer, Ferrer, iRegene, Servier, UCB, Roche; and received grants from AXA and the ICM Foundation outside of this work. OR has acted as a scientific advisor for drug companies developing antiparkinsonian medications (Abbott, Abbvie, Acorda, Adamas, BIAL, Biogen, Boehringer‐Ingelheim, Cynapsus, GSK, Impax, Merck, Osmotica, Oxford‐Biomedica, Lundbeck, Novartis, Prexton, Servier, Sunovion, TEVA, UCB, Zambon). Margherita Fabbri received Honoraria to speak from AbbVie, ORKYN, and BIAL, consultancies from BIAL and LVL Medical; Grant from France Parkinson, HORIZON 2022 French Ministry of Health and MSA Coalition.